GeneMedix Overview

  • Founded
  • 1997
  • Status
  • Acquired/​Merged
  • Employees
  • 13
  • Latest Deal Type
  • M&A
  • Latest Deal Amount
  • $28.7M
Latest Deal Amount

GeneMedix General Information


Developer and manufacturer of generic biopharmaceuticals. The company develops erythropoietin (EPO) for the treatment of anaemia, recombinant insulin for the treatment of diabetes, and interferon alfa for the treatment of hepatitis C and hepatitis B.

Contact Information

Ownership Status
Financing Status
Formerly VC-backed
Primary Industry
Other Industries
Drug Discovery
Other Pharmaceuticals and Biotechnology
Reliance Life Sciences
Primary Office
  • Rosalind Franklin House
  • Fordham Road, Newmarket
  • Suffolk CB8 7XN
  • England, United Kingdom
+44 01638 000000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

GeneMedix Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Merger/Acquisition 07-Feb-2007 $28.7M 00.000 000.00 Completed Generating Revenue
3. PIPE 30-Sep-2004 00.000 00.000 Completed Generating Revenue
2. PIPE 15-Apr-2004 $3.47M $5.96M Completed Generating Revenue
1. PIPE 24-Jun-2003 $2.49M $2.49M Completed Generating Revenue
To view GeneMedix’s complete valuation and funding history, request access »

GeneMedix Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

GeneMedix Former Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Proseed Capital Venture Capital Minority 000 0000 000000 0
To view GeneMedix’s complete investors history, request access »